We're thrilled to share that AMBOSS has acquired @nejmkplus from the esteemed @NEJM group! This is a game-changer in our mission to transform medical education globally. Get ready for exciting innovations ahead! Learn more about the acquisition → https://t.co/SCxP6gvg1W

It's #MatchWeek. Who's ready? #MatchDay #Match2024 #MedTwitter

🔎 Here are the studies from last week's edition of the One-Minute Telegram. Click the link below to access the most important findings broken down into one minute of reading. → https://t.co/8cZGglrUJC

🔬 Here are the studies from last week’s edition of the One-Minute Telegram. Subscribe now to access the most important findings broken down into one minute of reading. → https://t.co/uzjunNJ9dY

Stay informed, effortlessly. Subscribe to the One-Minute Telegram for this week’s studies, distilled into a single minute of reading. → https://t.co/uzjunNIBoq

💊 Dive into the studies from last week's One-Minute Telegram. Subscribe for key insights in just 60 seconds of reading! → https://t.co/uzjunNIBoq

🔬 Here are the studies from this week’s edition of the One-Minute Telegram. Subscribe now to access the most important findings broken down into one minute of reading. → https://t.co/uzjunNIBoq

📚 Here are the studies from last week’s edition of the One-Minute Telegram. Subscribe now to access the most important findings broken down into one minute of reading. → https://t.co/uzjunNIBoq

Here are the studies from last week’s edition of the One-Minute Telegram. Subscribe now to access the most important findings broken down into one minute of reading. 👉 https://t.co/uzjunNIBoq

Here are the studies from this week’s edition of the One-Minute Telegram. Subscribe now to access the most important findings broken down into one minute of reading. https://t.co/uzjunNIBoq

8/ How much would fast, affordable, and reliable point-of-care nasopharyngeal pathogen testing change your practice around antibiotic prescribing for acute upper respiratory tract infections? Let us know in the thread!

7/ Limitations? Limited generalizability to children with mild or severe sinusitis. Study participants had higher PRSS scores than those who declined to participate and patients with severe sinusitis were excluded.

6/Mean PRSS improvement was greatest in the subgroup with culture-proven NPP and similar across groups regardless of nasal discharge color. Higher incidence of diarrhea in antibiotic group than in placebo group: 11.4% vs. 4.7% (RR 2.40; 95% CI, 1.26–4.59).

5/ Results: Mean PRSS scores were significantly lower in the antibiotic group than in the placebo group. Median time to symptom resolution was lower in the antibiotic group (7 days) than in the placebo group (9 days).

4/Subgroups stratified by presence or absence of green or yellow nasal discharge. NPP bacterial cultures obtained at beginning and end of study.

3/ Pop: 515 children aged 2–11 (54% male, 52% White, 89% non-Hispanic) meeting criteria for acute sinusitis. Design: Randomized 1:1 to amox/clav 90/6.4 mg/kg/day PO or placebo. Primary outcome: daily symptom burden based on the Pediatric Rhinosinusitis Symptoms Scale (PRSS).

2/In this NIH-funded randomized clinical trial in @JAMA_current by Nader Shaikh et al, antibiotics were more effective than placebo in reducing symptoms of acute sinusitis in kids, but mainly when nasopharyngeal pathogens (NPP) were present.

1/In acute sinusitis, the color of nasal discharge is snot important. Welcome to our weekly #OMTweetorial. #MedTwitter #MedEd #EBM #JournalClub #AntibioticStewardship #Pediatrics

6/Mean PRSS improvement was greatest in the subgroup with culture-proven NPP and similar across groups regardless of nasal discharge color. Higher incidence of diarrhea in antibiotic group than in placebo group: 11.4% vs. 4.7% (RR 2.40; 95% CI, 1.26–4.59).

5/ Results: Mean PRSS scores were significantly lower in the antibiotic group than in the placebo group. Median time to symptom resolution was lower in the antibiotic group (7 days) than in the placebo group (9 days).